{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:16:50Z","timestamp":1791908210753,"version":"4.3.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81802725"],"award-info":[{"award-number":["81802725"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Foundation of Sun Yat-sen University Cancer Center for Distinguished Young Scholar","award":["PT04180201"],"award-info":[{"award-number":["PT04180201"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00432-021-03700-9","type":"journal-article","created":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T07:35:52Z","timestamp":1624865752000},"page":"1159-1169","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Efficacy and safety of anti-PD-1 inhibitor combined with nab-paclitaxel in Chinese patients with refractory melanoma"],"prefix":"10.1007","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4410-2629","authenticated-orcid":false,"given":"Jing-jing","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiu-hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Dingv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-dan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-zhi","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-jing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-xue","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3011-1134","authenticated-orcid":false,"given":"Xiao-shi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,28]]},"reference":[{"key":"3700_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/cdd.2013.67","volume":"21","author":"L Bracci","year":"2014","unstructured":"Bracci L, Schiavoni G, Sistigu A, Belardelli F (2014) Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ 21:15\u201325. https:\/\/doi.org\/10.1038\/cdd.2013.67","journal-title":"Cell Death Differ"},{"key":"3700_CR2","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","volume":"23","author":"S Champiat","year":"2017","unstructured":"Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S (2017) Hyperprogressive disease is a new pattern of progression in cancer patients treated by Anti-PD-1\/PD-L1. Clin Cancer Res 23:1920\u20131928. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1741","journal-title":"Clin Cancer Res"},{"key":"3700_CR3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/1471-2407-11-85","volume":"11","author":"Z Chi","year":"2011","unstructured":"Chi Z, Li S, Sheng X, Si L, Cui C, Han M (2011) Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases. BMC Cancer 11:85. https:\/\/doi.org\/10.1186\/1471-2407-11-85","journal-title":"BMC Cancer"},{"key":"3700_CR4","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1158\/1078-0432.CCR-05-1634","volume":"12","author":"N Desai","year":"2006","unstructured":"Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12:1317\u20131324. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-1634","journal-title":"Clin Cancer Res"},{"key":"3700_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1634\/theoncologist.2010-0190","volume":"16","author":"C Garbe","year":"2011","unstructured":"Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM (2011) Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 16:5\u201324. https:\/\/doi.org\/10.1634\/theoncologist.2010-0190","journal-title":"Oncologist"},{"key":"3700_CR6","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.1158\/1078-0432.CCR-07-4592","volume":"14","author":"ER Gardner","year":"2008","unstructured":"Gardner ER, Dahut WL, Scripture CD, Jones J, Aragon-Ching JB, Desai N (2008) Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res 14:4200\u20134205. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-4592","journal-title":"Clin Cancer Res"},{"key":"3700_CR7","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.1158\/1078-0432.CCR-07-4025","volume":"14","author":"CT Garnett","year":"2008","unstructured":"Garnett CT, Schlom J, Hodge JW (2008) Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res 14:3536\u20133544. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-4025","journal-title":"Clin Cancer Res"},{"key":"3700_CR8","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1305133","volume":"369","author":"O Hamid","year":"2013","unstructured":"Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:134\u2013144. https:\/\/doi.org\/10.1056\/NEJMoa1305133","journal-title":"N Engl J Med"},{"key":"3700_CR9","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/annonc\/mdz011","volume":"30","author":"O Hamid","year":"2019","unstructured":"Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R (2019) Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol 30:582\u2013588. https:\/\/doi.org\/10.1093\/annonc\/mdz011","journal-title":"Ann Oncol"},{"key":"3700_CR10","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1002\/ijc.28070","volume":"133","author":"JW Hodge","year":"2013","unstructured":"Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang KY, Ferrone S (2013) Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer 133:624\u2013636. https:\/\/doi.org\/10.1002\/ijc.28070","journal-title":"Int J Cancer"},{"key":"3700_CR11","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711\u2013723. https:\/\/doi.org\/10.1056\/NEJMoa1003466","journal-title":"N Engl J Med"},{"key":"3700_CR12","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/bjd.15510","volume":"177","author":"C Karimkhani","year":"2017","unstructured":"Karimkhani C, Green AC, Nijsten T, Weinstock MA, Dellavalle RP, Naghavi M (2017) The global burden of melanoma: results from the Global Burden of Disease Study 2015. Br J Dermatol 177:134\u2013140. https:\/\/doi.org\/10.1111\/bjd.15510","journal-title":"Br J Dermatol"},{"key":"3700_CR13","doi-asserted-by":"publisher","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-16-3133","volume":"23","author":"S Kato","year":"2017","unstructured":"Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R (2017) Hyperprogressors after Immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res 23:4242\u20134250. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-3133","journal-title":"Clin Cancer Res"},{"key":"3700_CR14","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD (2019) Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 381:1535\u20131546. https:\/\/doi.org\/10.1056\/NEJMoa1910836","journal-title":"N Engl J Med"},{"key":"3700_CR15","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.tranon.2018.08.005","volume":"11","author":"HY Ng","year":"2018","unstructured":"Ng HY, Li J, Tao L, Lam AK, Chan KW, Ko JMY (2018) Chemotherapeutic treatments increase PD-L1 expression in esophageal squamous cell carcinoma through EGFR\/ERK activation. Transl Oncol 11:1323\u20131333. https:\/\/doi.org\/10.1016\/j.tranon.2018.08.005","journal-title":"Transl Oncol"},{"key":"3700_CR16","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J (2018) Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 379:2040\u20132051. https:\/\/doi.org\/10.1056\/NEJMoa1810865","journal-title":"N Engl J Med"},{"key":"3700_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0226869","volume":"14","author":"D Perlstein","year":"2019","unstructured":"Perlstein D, Shlagman O, Kogan Y, Halevi-Tobias K, Yakobson A, Lazarev I (2019) Personal response to immune checkpoint inhibitors of patients with advanced melanoma explained by a computational model of cellular immunity, tumor growth, and drug. PLoS ONE 14:e0226869. https:\/\/doi.org\/10.1371\/journal.pone.0226869","journal-title":"PLoS ONE"},{"key":"3700_CR18","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320\u2013330. https:\/\/doi.org\/10.1056\/NEJMoa1412082","journal-title":"N Engl J Med"},{"key":"3700_CR19","doi-asserted-by":"publisher","unstructured":"Rossi E, Schinzari G, Maiorano BA, Indellicati G, Di Stefani A, Pagliara MM (2020) Efficacy of i- mmune checkpoint inhibitors in different types of melanoma. Hum Vaccin Immunother: 1\u201310. https:\/\/doi.org\/10.1080\/21645515.2020.1771986","DOI":"10.1080\/21645515.2020.1771986"},{"key":"3700_CR20","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.tranon.2019.02.007","volume":"12","author":"L Si","year":"2019","unstructured":"Si L, Zhang X, Shu Y, Pan H, Wu D, Liu J (2019) A phase Ib study of pembrolizumab as second-line therapy for chinese patients with advanced or metastatic melanoma (KEYNOTE-151). Transl Oncol 12:828\u2013835. https:\/\/doi.org\/10.1016\/j.tranon.2019.02.007","journal-title":"Transl Oncol"},{"key":"3700_CR21","doi-asserted-by":"publisher","unstructured":"Soliman HH (2017) nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors. Onco Targets Ther 10:101\u2013112. https:\/\/doi.org\/10.2147\/OTT.S122974","DOI":"10.2147\/OTT.S122974"},{"key":"3700_CR22","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1158\/1078-0432.CCR-19-3922","volume":"26","author":"B Tang","year":"2020","unstructured":"Tang B, Chi Z, Chen Y, Liu X, Wu D, Chen J (2020) Safety, efficacy, and biomarker analysis of toripalimab in previously treated advanced melanoma: results of the POLARIS-01 multicenter phase II trial. Clin Cancer Res 26:4250\u20134259. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3922","journal-title":"Clin Cancer Res"},{"key":"3700_CR23","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1158\/2326-6066.CIR-16-0325","volume":"5","author":"PC Tumeh","year":"2017","unstructured":"Tumeh PC, Hellmann MD, Hamid O, Tsai KK, Loo KL, Gubens MA (2017) Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC. Cancer Immunol Res 5:417\u2013424. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0325","journal-title":"Cancer Immunol Res"},{"key":"3700_CR24","doi-asserted-by":"publisher","unstructured":"Tyrrell H, Payne M (2018) Combatting mucosal melanoma: recent advances and future perspectives. Melanoma Manag 5:MMT11. https:\/\/doi.org\/10.2217\/mmt-2018-0003","DOI":"10.2217\/mmt-2018-0003"},{"key":"3700_CR25","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/jid.2012.341","volume":"133","author":"S Ugurel","year":"2013","unstructured":"Ugurel S, Paschen A, Becker JC (2013) Dacarbazine in melanoma: from a chemotherapeutic drug to an immunomodulating agent. J Invest Dermatol 133:289\u2013292. https:\/\/doi.org\/10.1038\/jid.2012.341","journal-title":"J Invest Dermatol"},{"key":"3700_CR26","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.molimm.2007.08.013","volume":"45","author":"P Zhang","year":"2008","unstructured":"Zhang P, Su DM, Liang M, Fu J (2008) Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. Mol Immunol 45:1470\u20131476. https:\/\/doi.org\/10.1016\/j.molimm.2007.08.013","journal-title":"Mol Immunol"},{"key":"3700_CR27","doi-asserted-by":"publisher","first-page":"741","DOI":"10.7150\/jca.37966","volume":"11","author":"F Zhang","year":"2020","unstructured":"Zhang F, Huang D, Li T, Zhang S, Wang J, Zhang Y (2020) Anti-PD-1 therapy plus chemotherapy and\/or bevacizumab as second line or later treatment for patients with advanced non-small cell lung cancer. J Cancer 11:741\u2013749. https:\/\/doi.org\/10.7150\/jca.37966","journal-title":"J Cancer"},{"key":"3700_CR28","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.immuni.2013.06.014","volume":"39","author":"L Zitvogel","year":"2013","unstructured":"Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G (2013) Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 39:74\u201388. https:\/\/doi.org\/10.1016\/j.immuni.2013.06.014","journal-title":"Immunity"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03700-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-021-03700-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03700-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T07:29:35Z","timestamp":1650353375000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-021-03700-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,28]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["3700"],"URL":"https:\/\/doi.org\/10.1007\/s00432-021-03700-9","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,28]]},"assertion":[{"value":"12 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were conducted in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Written informed consent for publication was obtained from all authors and participants in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}